Viron Therapeutics, Inc. has signed an agreement with Diosynth Biotechnology for process development, scale-up, and clinical manufacturing for its lead product candidate, VT-111, currently in Phase II trials for the treatment of inflammation associated with Acute Coronary Syndrome (ACS).
"We are very pleased to be working with Viron," said Frank Tielens, president of Diosynth Biotechnology. "Our experience in technology transfer, in process development and in cGMP production and our regulatory history have certainly been noticed and appreciated by the industry." Mr. Tielens added, "Because of these strengths, we have been rewarded with innovative customers such as Viron whose VT-111 product was recently identified as one the 10 most promising cardiovascular drug candidates in development."
"We have entrusted Diosynth with the clinical manufacturing of our lead drug candidate, VT-111, as they have proven themselves to be world leaders in this area," stated Neil K. Warma, president and chief executive officer of Viron. "The manufacturing process developed will ultimately support pivotal trials and the eventual market launch of VT-111, which is currently being tested in a multi-center Phase II trial, and we are pleased to have such a strong partner in Diosynth," added Mr. Warma.